Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) After A Viremic Event: A Pooled Analysis of Studies in People with HIV
Most participants receiving B/F/TAF experienced no viremic events. The vast majority of viremic events resolved with B/F/TAF continuation, without the need for treatment change.
Authors
- Michelle L. D’Antoni (ORCID: https://orcid.org/0009-0004-5395-7022)
- Chloe Orkin (ORCID: https://orcid.org/0000-0001-6168-6745)
- Karam Mounzer (ORCID: https://orcid.org/0000-0001-8537-7103)
- Hailin Huang (ORCID: https://orcid.org/0000-0002-5012-9991)
- José Ramón Arribas (ORCID: https://orcid.org/0000-0002-7410-9450)
- Laurie A. VanderVeen
- Kristen Andreatta
- Jason T. Hindman (ORCID: https://orcid.org/0000-0003-1513-3423)
- Christian Callebaut (ORCID: https://orcid.org/0000-0003-4721-2572)
- Yazdan Yazdanpanah
- Anton Pozniak
- Axel Baumgarten
- Hui Liu (ORCID: https://orcid.org/0009-0003-3273-6979)
Institutions
- Queen Mary University of London (GB)
- Chelsea and Westminster Hospital NHS Foundation Trust (GB)
- Hospital Universitario La Paz (ES)
- Assistance Publique – Hôpitaux de Paris (FR)
- Centro de Investigación Biomédica en Red (ES)
- Gilead Sciences (Spain) (ES)
- Gilead Sciences (United States) (US)
- Hôpital Bichat-Claude-Bernard (FR)
- Philadelphia Fight (US)
Publication Details
- Journal
- Infectious Diseases and Therapy
- Published
- 2025-04-15
- DOI
- https://doi.org/10.1007/s40121-025-01153-y
- Citations
- 4
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 5.58
Funders
- Gilead Sciences